PCAC Peptide Review 2026: What FDA’s July Hearing Means for BPC-157, TB-500, and MOTS-c
This pcac peptide review 2026 tracks a specific FDA process, not a verdict. Seven peptides, including BPC-157, TB-500, and MOTS-c, are sitting in a regulatory gray zone while the Pharmacy Compounding Advisory Committee (PCAC) prepares to weigh in on whether they belong on a formal compounding list. Nothing has been decided yet, and the terminology matters more than the headlines suggest.
The Compound Universe Take: As of July 2026, 12 peptides were removed from FDA’s Category 2 “do not compound” list in April 2026, but removal is not approval. A PCAC meeting on July 23-24, 2026 will review seven of those peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) for possible addition to the Section 503A bulk drug substances list. FDA’s own career scientists have recommended against the change for all seven. No vote has happened and no rule has been finalized; consult a licensed prescriber or pharmacist for current compounding availability.
| Peptide(s) | Category 2 status | PCAC review date | Compounding status today |
|---|---|---|---|
| BPC-157 | Removed April 2026 | July 23, 2026 | Not on 503A list; not authorized |
| KPV | Removed April 2026 | July 23, 2026 | Not on 503A list; not authorized |
| TB-500 | Removed April 2026 | July 23, 2026 | Not on 503A list; not authorized |
| MOTS-c | Removed April 2026 | July 23, 2026 | Not on 503A list; not authorized |
| DSIP (emideltide) | Removed April 2026 | July 24, 2026 | Not on 503A list; not authorized |
| Semax | Removed April 2026 | July 24, 2026 | Not on 503A list; not authorized |
| Epitalon | Removed April 2026 | July 24, 2026 | Not on 503A list; not authorized |
| GHK-Cu (injectable), LL-37, Dihexa, PEG-MGF, Melanotan II | Removed April 2026 | Before end of February 2027 (second meeting) | Not on 503A list; not authorized |
What “PCAC” and “Category 2” actually mean
FDA sorts nominated compounding substances into three buckets. Category 1 has no identified safety signal blocking review. Category 2 carries a “significant safety risk” flag that bars 503A pharmacies from compounding. Category 3 covers substances with insufficient data to decide either way [1].
In September 2023, FDA placed 19 peptides into Category 2, closing the door on 503A compounding. PCAC is the outside expert panel FDA convenes to advise which bulk drug substances belong on the authorized 503A list. Its votes are recommendations; FDA is not bound by them, and rulemaking after a vote can take over a year [2][3].
The 12 peptides removed from Category 2 in April 2026
On April 16, 2026, FDA published a Federal Register notice confirming that 12 of the 19 Category 2 peptides were being removed from that list, following withdrawal of the original safety nominations: BPC-157, LL-37 (cathelicidin), Dihexa, DSIP (emideltide), Epitalon, GHK-Cu (injectable form), KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500 [1][2].
Removal from Category 2 is narrower than it sounds. It lifts the “significant safety risk” bar, but it does not place any of these 12 peptides on the Section 503A bulk drug substances list, and without that listing, 503A pharmacies still cannot legally compound them [1][2]. Some coverage has used language like “reinstated” or “legal again.” That framing is inaccurate: this is a neutral holding pattern, no longer explicitly barred but not yet authorized.
What the PCAC peptide review 2026 hearing covers
That same Federal Register notice convened a PCAC meeting for July 23-24, 2026 at FDA White Oak, with a virtual option, to evaluate seven of the 12 removed peptides for the 503A bulks list [2][3]. Day one (July 23) covers BPC-157, KPV, TB-500, and MOTS-c. Day two (July 24) covers DSIP, Semax, and Epitalon. The remaining five (GHK-Cu injectable, LL-37, Dihexa, PEG-MGF, Melanotan II) are slated for a second meeting before the end of February 2027 [2].
What the underlying research covers for the July docket
Animal: BPC-157, derived from a fragment of gastric protective protein, has the largest preclinical footprint of the seven, with rodent studies reporting gastric, intestinal, and tendon-tissue healing linked to VEGF-driven angiogenesis [4]. Animal: TB-500, a synthetic analog of thymosin beta-4, has older rodent wound-healing data tied to the same angiogenic pathway [5]. Animal / early human: MOTS-c is a mitochondrial-derived peptide studied for activating AMPK, the cell’s energy-sensing pathway, with human data still limited [6]. In-vitro / animal: KPV, a tripeptide fragment of alpha-melanocyte-stimulating hormone, is studied for NF-kB-mediated anti-inflammatory activity [7]. Animal / limited human: DSIP (emideltide), Semax, and Epitalon carry a smaller, largely non-U.S. research base tied to sleep, cognitive signaling, and pineal biology, with less controlled human data than the day-one peptides.
None of the seven has an FDA-approved indication. PCAC’s job in July is narrowly about compounding eligibility, not about validating any mechanism as proven therapy.
Why FDA’s own scientists are skeptical
NPR reported on July 8, 2026 that FDA career scientists, in briefing documents posted ahead of the hearing, recommended against changing the status of all seven peptides, citing insufficient evidence of effectiveness and safety [8]. That sits alongside reporting that some panel members have industry ties, a tension FDA-law researchers have flagged publicly [8]. A PCAC vote is advisory only; even a favorable vote would trigger a separate rulemaking process, not an immediate change to what a pharmacy may legally dispense.
Read this before assuming anything changed: As of July 2026, none of the 12 peptides discussed here are approved by FDA or listed on the Section 503A bulk drug substances list. Removal from Category 2 is not legalization, and a PCAC recommendation is not a final rule. This page summarizes the regulatory record; it is not medical advice, a dosing guide, or a statement about where or whether to obtain any compound. Confirm current status with a licensed prescriber or pharmacist before assuming availability.
Compounds outside the PCAC docket, for context
Not every related peptide is part of this review. Sermorelin remains compoundable under 503A today with a documented medical-necessity attestation, not open access [9]. Tesamorelin (Egrifta) and bremelanotide (Vyleesi) are FDA-approved drugs, outside the compounding-substance conversation entirely. CJC-1295, ipamorelin, and thymosin alpha-1 remain barred after a 2024 PCAC vote against them and sit outside the July 2026 docket [9].
| Compound | Regulatory status (US) | Note |
|---|---|---|
| Sermorelin | Compoundable under 503A | Requires documented medical-necessity attestation |
| Tesamorelin | FDA-approved (Egrifta) | Not a compounding question |
| Bremelanotide | FDA-approved (Vyleesi) | Not a compounding question |
| CJC-1295 / ipamorelin / thymosin alpha-1 | Barred from compounding | PCAC voted against in 2024; not on 2026 docket |
| Semaglutide / tirzepatide / liraglutide | Enforcement discretion ended; 503B bulks exclusion proposed | See GLP-1 compounding section below |
Where GLP-1 compounding stands, separately
The GLP-1 story runs on its own timeline and is not part of this PCAC docket. FDA’s initial October 2024 tirzepatide shortage-resolution decision was challenged in litigation and superseded by a December 19, 2024 declaratory order; tirzepatide’s shortage-driven compounding discretion ended February 18, 2025 (503A) and March 19, 2025 (503B) under that order. Semaglutide’s shortage was declared resolved in February 2025, and its compounding discretion ran longer, ending April 22, 2025 (503A) and May 22, 2025 (503B) [10]. Mass “essentially a copy” compounding of Ozempic, Wegovy, Mounjaro, or Zepbound is no longer legal outside narrow patient-specific exceptions.
On April 30, 2026, FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the Section 503B bulks list; comments closed June 29, 2026 and a final rule is pending [11]. FDA also ran warning-letter waves through 2026 against telehealth marketers and peptide sellers, including a 25-letter wave in June, targeting claims that compounded GLP-1s or “research use only” peptides equal approved drugs [12]. An “RUO” label does not shield a product marketed for human use.
Key takeaways
- PCAC peptide review 2026 is a process, not a decision. Twelve peptides left Category 2 in April 2026, but none moved onto the Section 503A bulks list, so compounding remains unauthorized [1][2].
- The July 23-24, 2026 hearing covers seven peptides, split BPC-157/KPV/TB-500/MOTS-c on day one and DSIP/Semax/Epitalon on day two [2][3].
- FDA’s own scientists recommended against the change for all seven peptides under review, citing insufficient safety and effectiveness data [8].
- Sermorelin, tesamorelin, and bremelanotide sit outside this docket entirely, on different legal footing than BPC-157 or TB-500 [9].
- GLP-1 compounding is a separate, largely closed lane, with a 503B bulks exclusion proposed for semaglutide, tirzepatide, and liraglutide in 2026 [10][11].
Frequently asked questions
What is the PCAC peptide review 2026?
It is a Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, where FDA advisors will evaluate whether seven peptides, including BPC-157, TB-500, and MOTS-c, should be added to the Section 503A bulk drug substances list for legal compounding.
Does removing a peptide from Category 2 make it legal?
No. Category 2 removal lifts the “significant safety risk” bar, but a peptide must also appear on the Section 503A bulks list before pharmacies can legally compound it. None of the 12 removed peptides are on that list as of July 2026.
Has FDA voted to approve BPC-157 or TB-500 for compounding?
No vote had occurred as of early July 2026. The PCAC hearing will produce advisory recommendations, not a binding decision, and any resulting rulemaking would follow separately and could take over a year.
Why do FDA’s career scientists oppose the change?
Briefing documents reported by NPR on July 8, 2026 show FDA staff scientists found insufficient evidence of effectiveness and safety to justify expanding compounding access to any of the seven peptides on the docket.
Is sermorelin part of this PCAC peptide review?
No. Sermorelin already has a compounding pathway under 503A with a documented medical-necessity attestation and is not part of the July 2026 hearing.
Are compounded GLP-1 drugs like semaglutide covered by this hearing?
No. GLP-1 compounding follows a separate regulatory track. FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the Section 503B bulks list in April 2026, and that proposal is unrelated to the peptide Category 2 removals discussed here.
The PCAC peptide review 2026 sits at the intersection of compounding law and peptide science, where the Pharmacy Compounding Advisory Committee weighs Section 503A bulk drug substance nominations against Category 2 safety findings for BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon, while adjacent tracks cover 503B outsourcing facilities, GLP-1 exclusions, and warning-letter enforcement against research-use-only marketing; Compound Universe follows each docket and Federal Register filing as it publishes, dated and sourced.
This pcac peptide review 2026 will keep changing shape as the July hearing produces recommendations and FDA decides whether to act on them, so treat every status above as a snapshot, not an outcome. Nothing here recommends obtaining, compounding, or using any peptide; confirm current status with a licensed prescriber or pharmacist before drawing conclusions.
Related reading: Compound Universe’s BPC-157 research page covers the underlying tissue-repair evidence in more depth | the MOTS-c research summary breaks down the AMPK-activation data referenced above | are peptides legal? explains the broader compounding framework this tracker sits inside.
References
- FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Federal Register, published April 16, 2026. Document 2026-07361.
- Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List. Insights, April 2026.
- FDA Advisory Committee Calendar. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.
- Multiple rodent-model reviews on BPC-157 angiogenesis and gastrointestinal/tendon healing via VEGF and nitric-oxide signaling (MDPI Pharmaceuticals, 2024-2026; PMC review literature). VERIFY single canonical PMID before publish.
- Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PMID 10469335.
- Lee C, et al. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. PMID 27216708 / PMC5116416.
- Getting SJ, Schioth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003. PMID 12750433.
- NPR. What’s behind the push to make peptide therapies more readily available. July 8, 2026.
- Frier Levitt. FDA Peptide Update: Removal from “Do Not Compound” List and What It Means for Pharmacies. 2026. (Sermorelin/CJC-1295/ipamorelin/thymosin alpha-1 compounding-status context; 2024 PCAC vote. VERIFY exact 2024 vote citation before publish.)
- FDA. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products. December 19, 2024 (revokes and replaces the October 2, 2024 order following litigation); compounding enforcement discretion ended February 18, 2025 (503A) / March 19, 2025 (503B). FDA. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products. February 21, 2025; compounding enforcement discretion ended April 22, 2025 (503A) / May 22, 2025 (503B).
- FDA. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcement, April 30, 2026; Federal Register, published May 1, 2026, Document 2026-08552.
- FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Press Announcement, 2026; follow-on 25-letter wave reported June 16, 2026.